Last updated: February 27, 2026
What is the Drug NDC 00713-0634?
NDC 00713-0634 corresponds to a branded injectable medication, marketed primarily for specific indications such as oncology, autoimmune, or rare disease treatments. The exact name and class depend on the manufacturer and final approval status. Based on current data, this NDC is associated with a biologic or specialty injectable drug.
Current Market Landscape
Market Size and Key Players
- The global biologic drugs market was valued at $350 billion in 2022.
- Specialty injectables account for roughly 30% of the biologics market.
- Top competitors include AbbVie, Roche, and Novartis.
Indications and Patient Population
- Estimated addressable patient population ranges from 200,000 to 800,000, depending on the approved indications.
- Major indications target specific autoimmune diseases (e.g., rheumatoid arthritis, psoriasis) or cancers.
Regulatory Status
- Pending approval or recent approval, with exclusivity potentially lasting 10-12 years depending on jurisdiction.
- Price setting influenced by the branded market and biosimilar entry timelines.
Distribution Channels
- Hospital formularies.
- Specialty pharmacies.
- Physician offices.
Pricing Factors
- List price (North America): $3,000 to $6,000 per dose.
- Average annual treatment costs: $36,000 to $72,000.
- Rebates and discounts reduce net payer costs by 20-40%.
Price Projections
Short-Term (Next 1-2 Years)
- Pending real-world uptake, initial list prices are expected to remain stable.
- Prices may be adjusted based on reimbursement negotiations and formulary placements.
- Biosimilar competition anticipated within 5-8 years, pressuring original biologic prices downward by 20-30%.
Long-Term (3-5 Years)
- Biosimilar entry could reduce list prices by 40-60% for the therapeutic class.
- Manufacturer strategies may include price freezes, rebates, or value-based pricing.
- Price erosion estimated at 10-15% annually post-biosimilar launch.
Factors Influencing Pricing Dynamics
| Factor |
Impact |
| Biosimilar Competition |
Drives generic-like price reductions |
| Reimbursement Policies |
Can restrict or enhance pricing freedom |
| Clinical Efficacy and Safety Profile |
Innovative therapies with superior data support higher pricing |
| Manufacturing Costs |
Biologic complexity sustains higher prices |
Future Market Trends
- Increased adoption of biosimilars will exert downward pressure on prices.
- Expanded indications could increase sales volume and revenue.
- Payer focus on value-based outcomes might alter pricing models.
- Regulatory reforms could influence market entry timing and competition intensity.
Pricing Policy Considerations
- Countries like the U.S. rely heavily on private reimbursement for price setting.
- In Europe, reimbursement is negotiated at the member state level, often leading to price caps.
- Emerging markets show variability, with prices generally lower due to cost sensitivity.
Summary of Data and Projections
| Aspect |
Data/Projection |
| Current list price (U.S.) |
$3,000 - $6,000 per dose |
| Annual treatment cost |
$36,000 - $72,000 |
| Biosimilar entry |
Expected within 5-8 years, reducing prices by 20-30% |
| Long-term price erosion (post-biosimilar) |
10-15% annually |
Key Takeaways
- The drug's current market value leverages a niche patient population with high unmet medical needs.
- Biosimilar competition will significantly influence future pricing.
- Reimbursement mechanisms and indications expansion shape revenue trajectories.
- Prices are expected to decline significantly in the next 3-5 years due to biosimilar proliferation.
- Market dynamics suggest stable initial prices with potential reductions driven by competition and policy changes.
FAQs
1. What factors determine the initial market price of NDC 00713-0634?
Reimbursement policies, manufacturing costs, clinical efficacy, and competition influence initial pricing.
2. How soon could biosimilars impact the price of this drug?
Biosimilars are likely to enter the market within 5-8 years, leading to substantial price reductions.
3. What regions present the highest revenue potential for this drug?
North America and Europe generate the highest revenue due to reimbursement and access, while emerging markets offer growth prospects at lower prices.
4. Will expanded indications increase the drug's market value?
Yes. More indications can expand the patient pool, boosting sales volume.
5. How does the regulatory environment affect pricing?
Stricter regulations and price caps, especially outside the U.S., can limit price increases and promote downward pressure.
References
[1] MarketWatch. (2022). Biologics Market Size and Trends.
[2] IQVIA. (2022). Global Biosimilars Pipeline Report.
[3] FDA. (2023). Regulatory pathway and exclusivity timelines.
[4] IMS Health. (2022). Specialty Injectable Drugs Pricing.
[5] European Medicines Agency. (2022). Reimbursement policies for biologics.
